1. Gridelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist 2007; 12(10): 1183-1193.

      2. Dundar E, Oner U, Peker BC, Metintas M, Isiksoy S, Ak G. The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. J Int Med Res 2008; 36(1): 88-95.

      3. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007; 13(7): 1961-1970.

      4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346(2): 92-98.

      5. Socinski MA. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am 2003; 9(2): 207-236.

      6. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apop­tosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005; 11(11): 3974-3986.

      7. Besse B, Ropert S, Soria JC. Targeted therapies in lung cancer. Ann Oncol 2007; 18 (Suppl 9): ix135-142.

      8. Giatromanolaki A, Sivridis E, Koukourakis MI. Tumour angiogenesis: vascular growth and survival. APMIS 2004; 112(7-8): 431-440.

      9. Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J 2002; 19(3): 557-570.

      10. Pang RWC, Poon RTP. Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag 2006; 2(2): 97-108.

      11. Hu J, Bianchi F, Ferguson M, Cesario A, Marga­ritora S, Granone P, Goldstraw P, Tetlow M, Ratcliffe C, Nicholson AG, Harris A, Gatter K, Pezzella F. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene 2005; 24(7): 1212-1219.

      12. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, Over­gaard J. Patterns of angiogenesis in non-small cell lung carcinoma. Cancer 2001; 91(8): 1500-1509.

      13. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005; 23(3): 193-200.

      14. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005; 23(14): 3243-3256.

      15. Gazdar AF, Minna JD. Angiogenesis and the multistage development of lung cancers. Clin Cancer Res 2000; 6(5): 1611-1612.

      16. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest 2007; 117(10) :2740-2750.

      17. Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett SM, Keane MP. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann NY Acad Sci 2004; 1028: 351-360.

      18. McClelland MR, Carskadon SL, Zhao L, White ES, Beer DG, Orringer MB, Pickens A, Chang AC, Aren­berg DA. Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol 2007; 36(3): 343-350.

      19. Lymn JS, Gallagher KL, Clunn GF, Fexby SE, Patel MK, Hughes AD. PDGF stimulates DNA synthesis in human vascular smooth muscle cells via a novel wortmannin-insensitive phosphatidylinositol 3-kinase. FEBS Lett. 2003; 555(3): 591-596.

      20. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF b-receptors. J Cell Biol 1994; 125(4): 917-928.

      21. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004; 15(4): 275-286.

      22. Ben-Shoshan J, Schwartz S, Luboshits G, Maysel-Auslender S, Barzelay A, Polak-Charcon S, Tzahor E, Barshack I, Barak A, Levkovitch-Verbin H, Keren G, George J. Constitutive expression of HIF-1a and HIF-2a in bone marrow stromal cells differentially promotes their proangiogenic properties. Stem Cells 2008; 26(10): 2634-2643.

      23. Hofmann HS, Hansen G, Richter G, Taege C, Simm A, Silber RE, Burdach S. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res 2005; 11(3): 1086-1092.

      24. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 1997; 62(5): 554-562.

      25. Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angio­genesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 2000; 162(5): 1957-1963.

      26. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing beva­cizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 2004; 22(11): 2184-2191.

      27. Vokes E, Herbst R, Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol 2006; 4(11 Suppl 23):1-10.

      28. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-2550.

      29. Wakelee H, Dubey S, Gandara D. Optimal adju­vant therapy for non-small cell lung cancer—how to handle stage I disease. Oncologist 2007; 12(3): 331-337.

      30. Ardizzoni A, Tiseo M. Combination of target agents: challenges and opportunities. J Thorac Oncol 2007; 2(Suppl 5): S4-6.

      31. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77: 25-79.

      32. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 2003; 13(5): 289-298.

      33. Le Tourneau C, Vidal L, Siu LL. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist Updat 2008; 11(3): 99-109.

      34. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody beva­cizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23(11): 2544-2555.

      35. Groen HJ, Smit EF, Dingemans A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(Suppl 18): Abstract 7625.

      36. Ryan AJ, Wedge SR. ZD6474—a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005; 92(Suppl 1): S6-13.

      37. Tiseo M, Franciosi V, Ardizzoni A. Multi-target inhibitors in non-small cell lung cancer (NSCLC). Ann Oncol 2006; 17(Suppl 2): ii55-ii57.

      38. Heymach JV, Johnson BE, Rowbottom JA, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Herbst RS. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. J Clin Oncol 2005; 23(Suppl 16): Abstract 3023.

      39. Adjei AA, Mandrekar S, Marks RS, Hanson LJ, Aranguren D, Jett JR, Simantov R, B. Schwartz B, Croghan GA. A phase I study of BAY 43-9006 and gefi­tinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). J Clin Oncol 2005; 23(Suppl 16): Abstract 3067.

      40. Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D, Cihon F, Reck M. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. JClin Oncol 2006; 24(Suppl 18): Abstract 7002.

      41. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60(8): 2178-2189.

      42. Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000; 6(3): 957-965.

      43. Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003; 63(21): 7301-7309.

      44. Cohen RB, Simon G, Langer CJ, Schol JR, McHale J, Eisenberg P, Hainsworth JD, Liau KF, Healey D. Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22(Suppl 14): Abstract 3014.

      45. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ. AZD2171: a highly potent, orally bio­available, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65(10): 4389-4400.

      46. Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003; 4(4): 231-236.